Advertisement

RedHill Biopharma's bowel syndrome drug study meets main goal

RedHill Biopharma's bowel syndrome drug study meets main goal
From Reuters - October 3, 2017

(Reuters) - RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome (IBS-D) met the main goal in a mid-stage study, with patients showing improvement in stool consistency.

The drug met the main goal but did not show enough promise in improving abdominal pain and overall response in patients.

The trial was testing a 12-mg dose of the once-daily oral drug, Bekinda, in patients with IBS-D, against a placebo.

U.S.-listed shares of the Tel Aviv-based company were down about 3 percent at $10.50 in premarket trading on Tuesday.

Advertisement

Continue reading at Reuters »